Clinical Trials Logo

Clinical Trial Summary

Background:

Small cell cancers are aggressive and grow fast. They can appear in the lungs and in other parts of the body. These tumors often don t respond well to treatment if they come back after chemotherapy. Treatment with two drugs combined may be able to help.

Objective:

To compare M6620 plus topotecan to topotecan alone in people with small cell lung cancer (SCLC). Also, to test the effects of M6620 plus topotecan in people with small cell cancer outside the lungs.

Eligibility:

People ages 18 and older with relapsed SCLC or small cell cancer outside the lungs

Design:

Participants will be screened with:

Physical exam

Blood and heart tests

CT scan

Tumor biopsy: This is mandatory for participants with SCLC. It is optional for those with small cell cancer outside the lungs.

Participants with SCLC will be randomly assigned to 1 of 2 groups: to receive either M6620 and topotecan or topotecan alone. Outside of the lungs small cell cancer participants will be assigned to receive both drugs.

Participants will receive treatment in 21-day cycles. They will get topotecan through a vein in the arm on days 1 5 of each cycle. Some participants also will receive M6620 through a vein in the arm on days 2 and 5 of each cycle.

Participants will have blood tests and physical exams every cycle. They will have CT scans every 6 weeks.

Participants will continue treatment as long as their cancer does not get worse and they can handle the side effects.

After treatment, participants will have visits every 3 months. Visits will include blood tests and CT scans.

Patients randomized 2:1 ie 2 times more likely to get the combination vs. single drug

Patients who receive single drug may receive the combination at the time of progression


Clinical Trial Description

Background:

- SCLC is the most aggressive and lethal form of lung cancer. It represents 15% of all lung cancers, with an annual incidence of over 34,000 cases in the United States alone.

- Relapsed SCLC has been traditionally classified into sensitive and resistant disease according to the type of response to first-line therapy and to treatment-free interval.

- Topotecan is Food and Drug Administration (FDA)-approved for patients with SCLC with chemotherapy-sensitive disease after failure of first-line chemotherapy (platinum and etoposide).

- Topotecan inhibits re-ligation of topoisomerase I-mediated single-strand DNA breaks leading to lethal double-strand DNA breaks (DSB).

- We showed that inhibition of ATR by short interfering RNA or VE-821 and its clinical derivative M6620 sensitizes tumor cells to TOP1 inhibitors.

- We found that a combination of an Ataxia telangiectasia and Rad3-related (ATR) inhibitor and topotecan can be safely combined and that heightening replicative stress in this manner can yield durable responses in small cell cancers and initiated a Phase 1/2 trial of the

combination.

- In this current study, we hypothesize that the combination of M6620 and topotecan can improve progression free survival (PFS) compared with topotecan alone in patients with relapsed SCLC.

- In the recently reported phase I clinical trial, we defined a safe and effective dose of topotecan plus M6820. The proposed randomized phase II trial is based on promising preliminary efficacy data seen in SCLC patients treated on phase I and the ongoing phase II trials.

Objectives:

-To determine if the combination of M6620 with topotecan will result in an improvement in progression-free survival (PFS) compared to topotecan alone in patients with relapsed small cell lung cancer (SCLC).

Eligibility:

-Patients enrolled to the primary cohort must have limited- or extensive-disease SCLC at diagnosis, with extensive disease at study entry with measurable disease at random assignment per RECIST 1.1. Both platinum-sensitive and platinum-resistant patients will

be included.

- Patients must be greater than or equal to18 years of age

- Patients who have received prior topotecan therapy are not eligible.

- Patients who are receiving any other investigational agents, and with uncontrolled intercurrent illness are not eligible.

Design:

- This study is an open label, randomized phase 2 study of patients with relapsed SCLC.

- SCLC patients who have failed prior therapy will be randomized 2:1 to receive either topotecan in combination with M6620 or topotecan alone.

- Patients will be stratified at the time of randomization for being sensitive or resistant/refractory to prior therapy.

- Patients on the topotecan monotherapy arm will be eligible to cross-over to receive the combination treatment at progression.

- It is expected that approximately 25-30 patients per year (about 2-3 patients per month) can be accrued onto the randomized portion of this trial, and thus accrual will be completed in approximately 2 years.

- A separate cohort of 20 patients with extrapulmonary small cell cancer will be accrued while the primary cohort is accruing and will only receive the combination therapy.

- This is planned as a multicenter study through CTEP. NCI CCR will be the lead and coordinating site ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04162041
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact Rasa Vilimas, R.N.
Phone (240) 858-3158
Email rasa.vilimas@nih.gov
Status Recruiting
Phase Phase 2
Start date November 20, 2019
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00750841 - Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours Phase 1
Withdrawn NCT05419817 - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Phase 2
Completed NCT02828930 - A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) Phase 1
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Completed NCT03258515 - A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers Phase 1
Terminated NCT03225105 - M3541 in Combination With Radiotherapy in Solid Tumors Phase 1
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT03634982 - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Phase 1
Recruiting NCT04685226 - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT06036121 - A Study of ADRX-0706 in Select Advanced Solid Tumors Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT01528046 - Metformin in Children With Relapsed or Refractory Solid Tumors Phase 1
Recruiting NCT05325866 - A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Completed NCT02759640 - A Phase I Trial of HS-10241 in Solid Tumors Phase 1
Withdrawn NCT01940601 - Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors Phase 2